SYRE as reported
Spyre Therapeutics, Inc. reported $0 of revenue over the trailing twelve months. 8 reported series are charted on this page, each one as filed.
$0
Revenue, trailing twelve months · to Q4 2024 · every figure below is as filed, with no scoring applied
- Net Income
- −$179M
Net Income · −13% year on year · trailing twelve months to Q2 2026
| Series | Latest | Year on year | As of |
|---|---|---|---|
| Revenue | $0 | n/a | Q4 2024 · 6 quarters behind |
| Net Income | −$179M | −13% | Q2 2026 |
| EPS | $1.48 | n/a | Q3 2024 · 7 quarters behind |
| Op Margin | −13707% | n/a | Q2 2023 · 12 quarters behind |
| Net Margin | −15635% | n/a | Q2 2023 · 12 quarters behind |
| ROE | −24% | n/a | Q2 2026 |
| ROA | −22% | n/a | Q2 2026 |
| Free Cash Flow | −$80M | n/a | Q4 2022 · 14 quarters behind |
Every figure straight from the statements as filed with the SEC, no scoring, no adjustment. Open a series for its full history.
Spyre Therapeutics, Inc. (SYRE) - Revenue & ProfitRevenue & ProfitSpyre Therapeutics, Inc. (SYRE)
Revenue (TTM)Net Income (TTM)
Powered byryufin.com